On October 14, SBP GROUP fell 3.08% in regular trading, trading at HK$5.185 per share, with turnover of HK$175 million.
The most recent market update points to broad weakness across Hong Kong-listed innovative drug and pharmaceutical names, with SBP GROUP declining alongside peers rather than on a fresh company-specific negative announcement.
Recent company news showed SBP GROUP repurchased 7.4 million shares on October 13 for about HK$39.56 million at HK$5.325 to HK$5.35 per share, following earlier pipeline and licensing developments, including completion of enrollment in a Phase III COPD study and an overseas biosimilar licensing deal. However, the latest session move coincided with a softer pharmaceuticals tape, where CSPC PHARMA fell 2.54%, HANSOH PHARMA fell 2.92%, ASYMCHEM fell 4.1%, while HUTCHMED rose 1.8%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
